The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s hyperphosphatemia treatment market report forecasts the hyperphosphatemia treatment market size to grow to $6.27 Billion by 2027, with a CAGR (compound annual growth rate) of more than 12%.

Learn More On The Hyperphosphatemia Treatment Market Report 2023 – https://www.thebusinessresearchcompany.com/report/hyperphosphatemia-treatment-global-market-report

Hyperphosphatemia Treatment Market Size Forecast
The global hyperphosphatemia treatment market is expected to grow from $3.57 billion in 2022 to $3.98 billion in 2023 at a compound annual growth rate (CAGR) of 11.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The hyperphosphatemia treatment market size is expected to grow to $6.27 billion in 2027 at a CAGR of 12.1%.

North America held the largest hyperphosphatemia treatment market share, and Asia-Pacific was the fastest-growing region in 2022.

Key Hyperphosphatemia Treatment Market Driver ­– Increase Chronic Diseases Among Patients
According to the World Health Organization (WHO), chronic disease prevalence is predicted to increase by 57% by the year 2020. According to the United States, the Renal Data System estimates that there are more than 300,000 patients with end-stage renal disease in the United States. There has been an increase in hyperphosphatemia among patients with end-stage renal disease (ESRD), thus contributing to an increase in demand for hyperphosphatemia treatment or drugs.

Request for A Sample Of The Global Hyperphosphatemia Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=5852&type=smp

Key Hyperphosphatemia Treatment Market Trend – Increasing Research And Development Activities
The company in hyperphosphatemia treatment are focused on research and development activities for the development of innovative therapies for the treatment of renal diseases and related chronic conditions. For instance, in May 2021, Alebund Pharmaceuticals, a Shanghai-based biopharmaceutical company, raised $60 million in a Series B round to accelerate its development activities of innovative drugs and solutions for the treatment of renal diseases, including hyperphosphatemia.

Hyperphosphatemia Treatment Market Segment
1) By Product: Sevelamer, Calcium-Based Phosphate Binders, Iron-Based Phosphate Binders, Lanthanum Carbonate, Other products
2) By Distribution channel: Hospital Pharmacy, Retail Pharmacy, Online stores

Hyperphosphatemia Treatment Market Major Players and Strategies
Major players in the hyperphosphatemia treatment market are Sanofi, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Akebia Therapeutics, Inc., Vifor Pharma Management Ltd., Lupin Limited, Ardelyx, Inc., Unicycive Therapeutics, Inc., Keryx Biopharmaceuticals, Zeria Pharmaceutical, Fresenius Medical Care, Shire, Ultragenyx Pharmaceutical, Inc., Sun Pharmaceutical Industries, Ltd., Akebia Therapeutics, Inc., and AMAG Pharmaceuticals, Inc.

In December 2020, Unicycive, a US-based company that develops novel treatments across multiple therapeutic areas, acquired Renazorb for an undisclosed amount. This acquisition will help Renazorb rapidly develop an alternate treatment for hyperphosphatemia supported by an extended history of the utilisation of lanthanum compounds for phosphate binding but with a potential to significantly enhance simple dosing and thereby improve patient adherence. Renazorb is a US-based company that’s a non-aluminium, non-calcium, phosphate binder manufactured employing a patent-protected nanotechnology process.

The Hyperphosphatemia Treatment Global Market Report 2023 covers regional data on hyperphosphatemia treatment market size, hyperphosphatemia treatment market trends and drivers, opportunities, strategies, and hyperphosphatemia treatment market competitor analysis. The countries covered in the hyperphosphatemia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Hyperphosphatemia treatment refers to a class of drug that boosts renal excretion to treat patients’ hyperphosphatemia. The most efficient way to do this is through volume replenishment with saline and forced diuresis with a loop diuretic like furosemide or bumetanide.

View More Reports Related To The Hyperphosphatemia Treatment Market –
Gastrointestinal Bleeding Treatment Devices Global Market Report 2023
Gastrointestinal Devices Global Market Report 2023
Hemodialysis And Peritoneal Dialysis Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: